BONE TISSUE CONTAINS CGRP-immunoreactive nerve fibers whose increased concentrations during bone development and regeneration suggest they are directly involved in the local regulation of bone remodeling (18 -20) . Further evidence shows that CGRP, which is derived from alternative splicing of calcitonin (CT) gene mRNA (2) , plays a role in bone metabolism. It inhibits osteoclastic bone resorption by directly blocking osteoclast activation (1, 21, 49) or indirectly regulating the osteoblast release of cytokines, such as interleukin-1 (28) and TNF-␣ (31) , that can affect osteoclast function. When administered to ovariectomized rats, CGRP inhibits bone resorption but not bone formation (44) . Moreover, transgenic mice overexpressing CGRP in osteoblasts have increased bone density (3) . Various human osteoblast cell lines and normal human osteoblast-like cells express mRNAs for CT and CGRP (10) and their receptors (46) . On these cells, CGRP increases both cell proliferation (47) and the production of insulin growth factor 1 (45) . Activated CGRP receptors stimulate both adenylyl cyclase activity (30) and phospholipase C (11) , which respectively stimulates cAMP production and activation of protein kinase A (PKA), and increase intracellular free calcium levels (6) with subsequent protein kinase C activation (11) . It has been shown that the activation of protein kinase C is involved in CGRP-induced osteoblast proliferation (46) . CGRP also acts on murine osteoblast ATP-sensitive K ϩ channels to attenuate Ca 2ϩ influx across the plasma membrane (22) . The activation of these pathways leads to changes in osteoblast gene expression by means of transcriptional and/or posttranscriptional mechanisms.
In normal bone remodeling, osteoblastic bone formation follows osteoclastic bone resorption along a hierarchical sequence of events. Osteoblast function is intimately tied to osteoclast activity as a result of the osteoblast production of essential cytokines. The osteoprotegerin/receptor activator of nuclear factor-B ligand/receptor activator of nuclear factor B (OPG/RANKL/RANK) system plays a key role in the cross-talk between osteoblasts and osteoclasts (48) . RANKL and OPG are members of a ligand-receptor system that directly regulates osteoclast differentiation and bone resorption. OPG is a member of the tumor necrosis factor receptor superfamily that is produced by osteoblastic lineage cells (16, 39) in the form of a 55-kDa monomer or 110-kDa dimer, and, because it lacks transmembrane and cytoplasmic domains, it is secreted by cells of osteoblastic lineage as a soluble protein (39, 48) . The soluble and membranous forms of RANKL are preferentially produced by osteoblasts, whereas the specific receptor, RANK, is expressed on osteoclast progenitors. RANKL binds to RANK, which leads to osteoclast activation (25) , or to OPG, thereby preventing osteoclast activation. RANKL stimulates osteoclast formation, fusion, and activation, and is essential for osteoclast survival (16) . Both osteoblasts and osteoclasts individually contribute to bone remodeling, but the type and extent of the remodeling depends on their cell-to-cell interactions. Increased RANKL/RANK signaling leads to high bone turnover with stimulated osteoblastic bone formation (34) . Hormones, growth factors, cytokines, and prostaglandins regulate these processes through their direct effects on bone cells and the OPG/RANKL/RANK system (7, 40) . Several osteotropic hormones, cytokines, and drugs affect this system by activating the cAMP pathway (5, 12, 24) . Because CGRP stimulates cAMP production in human osteoblasts (47) , it was investi-gated whether the effect of CGRP on bone is, at least in part, mediated by the OPG/RANKL/RANK system. For this purpose, we studied the effects of CGRP on OPG and RANKL expression and production in cultured human osteoblast-like cells (hOB). We analyzed the presence of calcitonin receptorlike receptor (CLR) and receptor-activity-modifying proteins (RAMPs), which are important for the ligand specificity of CGRP receptors (29) . Furthermore, we evaluated whether or not CGRP, by modulating the OPG/RANKL/RANK system in hOB, could influence osteoclastogenesis in cultured human peripheral blood mononuclear cells (PBMCs).
MATERIALS AND METHODS
Drugs. Human ␣CGRP was from Phoenix Pharmaceuticals, Belmont, CA; CGRP 8 -37 from Peninsula, St. Helen, UK; human recombinant macrophage colony-stimulating factor (hM-CSF) and human recombinant RANKL (Peprotech, Rocky Hill, NJ); 1,25(OH) 2D3 from Hoffmann-LaRoche, Basel, Switzerland; and dibutyryl cAMP (dBcAMP), forskolin (FSK), and H89 from Sigma, Milan, Italy.
Osteoblast-like cell cultures. Human bone cells were established in culture by means of a modified version of the Gehron Robey and Termine procedure (14) using trabecular bone samples obtained from waste materials during orthopedic surgery for degenerative diseases or traumatic fractures of the femoral neck requiring osteotomy. None of the operated patients (aged 51-73 yr) had any metabolic or malignant bone diseases and all of them gave their written consent for the use of the waste material. No significant trend related to donor age was observed in any of the effects studied.
Briefly, the trabecular bone was cut into small pieces (2 ϫ 2 ϫ 2 mm) and thoroughly washed with commercial standardized Joklik's modified MEM (Sigma, Milan, Italy) serum-free medium, to remove nonadherent marrow cells. The pieces were incubated with rotation at 37°C for 30 min with the same medium containing 0.5 mg/ml type IV collagenase (Sigma), and collagenase digestion was stopped by the addition of Iscove's modified Dulbecco's medium (Eurobio, Les Ulis, France) containing 10% fetal bovine serum (FBS; HyClone, Logan, UT). Between eight and ten pieces for each patient were then placed in 25 cm 2 flasks and cultured in Iscove's modified Dulbecco's medium containing 10% FBS, 100 U/ml penicillin, 100 g/ml streptomycin, 50 U/ml mycostatin, and 0.25 g/ml amphotericin B; the culture medium was changed every 2-3 days. The cells began to migrate within 1-2 wk and reached confluence after 1 mo. They were tested for alkaline phosphatase and osteocalcin production after 1,25(OH) 2D3 10 Ϫ8 M to ensure that they were endowed with osteoblast characteristics: alkaline phosphatase was determined in the cell layer solubilized with 0.5 ml 0.1% SDS by measuring the reduction in p-nitrophenol phosphate (Roche Diagnostics, Basel, Switzerland); osteocalcin was measured by chemiluminescence assay (Nichols Advantage, San Juan Capistrano, CA). All of the cells were used at first passage to reduce the possibility of phenotype changes. Conditioned media were collected after 48 h of CGRP treatment of hOB cultures, filtered, and stored at Ϫ80°C until use.
Isolation of cells from human peripheral blood. Human PBMCs were isolated by Ficoll-Paque sedimentation and adherence from the peripheral blood of different healthy donors (13) . Approximately 20 ml of blood were diluted 1:1 with ␣MEM (Sigma, Milan, Italy), layered over 20 ml of lymphocyte separation medium (Cambrex Bio Science, Walkersville, MD) and centrifuged at 2,300 rpm for 20 min. The mononuclear cell-rich layer at the interface was removed and washed twice in ␣MEM, and the pellet was then resuspended in ␣MEM with 10% FBS. The number of cells in the suspension was finally counted in a Burker chamber after red blood cell lysis using a 5% (vol/vol) acetic acid solution. The PBMCs (3 ϫ 10 5 cells/well) were seeded on glass coverslips (13 mm diameter) in 24-well plates. After incubation at 37°C for 2 h, they were removed from the wells, washed vigorously in ␣MEM to remove nonadherent cells, and placed in new wells containing 1 ml of conditioned media with 10% FBS. These cultures were incubated for 21 days in the presence of 25 ng/ml hM-CSF and 0.1 ng/ml or 30 ng/ml hRANKL in conditioned media obtained from hOB treated or not with 10 Ϫ8 M ␣CGRP for 48 h. The culture medium was changed every 3-4 days.
Characterization of generated osteoclasts. After 21 days, the coverslips were removed and stained histochemically for the expression of tartrate-resistant acid phosphatase (TRAP), an osteoclast-associated marker (32) . The cells were fixed in citrate/acetone solution and stained for acid phosphatase using a commercially available kit (Sigma, St. Louis, MO). Multinucleated TRAP-positive (TRAPϩ) cells were then counted.
RT-PCR. Total RNA was extracted from osteoblast-like cells from eight different donors using TRIzol according to the manufacturer's instructions (Invitrogen Life Technology, Paisley, UK). The RNA pellets were dissolved in sterile distilled water and their concentrations were assessed by spectrophotometric analysis (OD260/280). One microgram of total RNA was retrotranscribed in a total volume of 25 l using an oligo(dT) primer (0.5 M), 200 units of Moloney murine leukemia virus reverse transcriptase, deoxynucleotides (0.5 mM), Moloney murine leukemia virus reaction buffer (1ϫ), and rRNasin ribonuclease inhibitor (1 U/l) (Promega, Madison, WI). Specific primers were constructed for the human CRLR, RAMP1, RAMP2, RAMP3, OPG, and RANKL on the basis of the sequences published in GenBank (Table 1) . PCR was performed in a final volume of 20 l containing cDNA (4 l of the RT-PCR solution), 1 mM primers, 10 mM of each deoxynucleotide triphosphate, Taq polymerase (0.5 units), and PCR buffer (1ϫ) supplied with MgCl2 (2 mM) (Promega), using a thermal cycler (Tpersonal; Whatman Biometra, Goettingen, 
hCLR, human calcitonin receptor-like receptor; Fw, forward; Rev, reverse; OPG, osteoprotegerin; RAMP, receptor activity modifying protein; RANKL, receptor activator of nuclear factor-B ligand. Sources represent GenBank accession numbers.
Germany) and the conditions are listed in Table 2 . The PCR products were finally analyzed on 2% Tris-acetate-EDTA agarose gel. The DNA ladder was the PCR Marker 50 -2000 bp and the PCR Low Ladder Set (100-bp ladder) (Sigma, Milan).
Real-time PCR. Relative OPG mRNA expression was evaluated by means of Real-time PCR in hOB obtained from different donors. After 48 h of culture in a serum-free medium, confluent hOB were treated with 10 Ϫ8 M CGRP for 3, 6, and 24 h in the presence or absence of the CGRP receptor antagonist, CGRP 8 -37 (10 Ϫ8 M), or with 5 ϫ 10
Ϫ5
M dBcAMP. Total RNA was isolated and reverse transcribed as previously described. OPG gene expression was relatively quantified on an ABI PRISM 7700 sequence detector (Applied Biosystems, Foster City, CA) using 10 ng cDNA for the RT-PCR solution in a final volume of 25 l. The primer-probe sets were purchased from Applied Biosystems. Real-time PCR was performed using FAM-labeled specific probes for OPG detection and VIC TM -labeled probes for detection of the GAPDH housekeeping gene used as an internal control. All of the primers were chosen to span exon junctions or to lie in different exons to prevent the amplification of genomic DNA. The real-time PCR protocol included an initial step of 2 min at 50°C and 10 min at 95°C, followed by 40 cycles of 15 s at 95°C and 1 min at 60°C. The data were collected during each extension phase of the PCR reaction, and analyzed using the SDS software package (Applied Biosystems). Threshold cycles were determined for each gene, with the relative expression of each target gene of interest being normalized against GAPDH. 1 Three replicates were performed for each experimental point, and the experiments were repeated four times using cells from different donors.
PKA assay. CGRP 10 Ϫ8 M was used for different incubation times (2, 15, 30, 60 , and 90 min), and the preincubations with H89 (2 ϫ 10 Ϫ6 M), a specific PKA inhibitor, took place 30 min before each CGRP (10 Ϫ8 M) treatment. The cells were then rinsed twice in cold PBS and solubilized in a lysis buffer containing 50 mM HEPES, 250 mM NaCl, 5 mM MgCl 2, 1% Triton, 10% glycerol, and 10 g/ml aprotinin, leupeptin, and phenylmethylsulfonyl fluoride, pH 7.4. PKA activity was evaluated using the PepTag assay (Promega): briefly, this assay uses a fluorescent peptide substrate highly specific for PKA whose phosphorylation alters its net charge from positive to negative, thus allowing its phosphorylated and nonphosphorylated forms to be rapidly separated on agarose gel. When the electrophoresis was completed, the bands were excised, solubilized, and evaluated by spectrofluorometry (excitation 568 nm; emission 592 nm). The results were expressed as ratios of the emitted fluorescence intensity of the treated and untreated cells.
OPG assay. Primary hOB cultures were seeded into 6-well multiwell plates and allowed to grow to confluence. After 48 h of culture in serum-free medium, they were treated for 48 h with increasing concentrations of CGRP (10 Ϫ11 M-10 Ϫ8 M) in the presence or absence of the CGRP antagonist, CGRP8-37 (10 Ϫ8 M), or the PKA inhibitor H89 (2 ϫ 10 Ϫ6 M). The same procedure was used for dBcAMP (5 ϫ 10 Ϫ5 M) and FSK (5 ϫ 10 Ϫ6 M). OPG concentrations were measured in the conditioned media using a commercial kit (OPG, Immundiagnostik, Bensheim, Germany), and the results (fmol/ 10 5 cells) expressed as the ratio of OPG secretion from treated and untreated cells.
RANKL assay. Soluble RANKL was measured using a commercial kit (Biomedica, Vienna, Austria) in the conditioned media of hOB cultured for 48 h in the presence or absence of CGRP (10 Ϫ8 M), or 1,25(OH)2D3 (10 Ϫ8 M). Cathepsin K assay. Cathepsin K was measured in the supernatants of cultured human PBMCs after 21 days of treatment with the conditioned media of hOB cultured for 48 h with or without CGRP (10 Ϫ8 M) using a commercial kit (Biomedica). Statistical analysis. The data were statistically analyzed with Prism version 4.00 for Windows (GraphPad Software, San Diego, CA; www.graphpad.com). The significance of the within group differences was assessed by means of one-way ANOVA for nonparametric values (Kruskal-Wallis test) and a multiple-comparison test (Dunn's test), and that of the between-group differences by means of the two-tailed Student's t-test. The CGRP dose-response curve of OPG production was analyzed using nonlinear regression analysis (sigmoidal doseresponse curve). The significance of the effect of H89 on CGRPinduced PKA activity was evaluated by means of two-way ANOVA and Bonferroni's multiple-comparison test.
RESULTS
The hOB expressed the components of a functioning CGRP receptor (CLR and RAMP1); RAMP2 was also present, but no RAMP3 expression was detected (Fig. 1) . Forty-eight hours of treatment with different concentrations of CGRP (10
Ϫ11

M-10
Ϫ8 M) significantly inhibited OPG secretion in a dosedependent manner, with an EC 50 of 1.08 ϫ 10 Ϫ10 M (Fig. 2) . The inhibitory effect was greatest (ϳ45%) at the concentration of 10 Ϫ9 M, and reached a plateau at 10 Ϫ8 M; a higher concentration of 10 Ϫ7 M was less effective (data not shown). Decreased OPG secretion was accompanied by an inhibitory effect on OPG expression in hOB. Figure 3A shows that OPG mRNA was constitutively expressed in primary hOB; Realtime PCR revealed that CGRP significantly inhibited OPG mRNA transcription after 6 h, and this effect was still present after 24 h (Fig. 3B) but had disappeared after 48 h, when OPG mRNA expression returned to baseline levels (data not shown). The inhibitory action of CGRP (10 Ϫ8 M) on OPG secretion (Fig. 4A) and expression (Fig. 4B ) in hOB was prevented by the peptide antagonist CGRP 8 -37 (10 Ϫ8 M), which per se had no effect. The treatment of hOB with dBcAMP (5 ϫ 10 Ϫ5 M), a nonhydrolyzable analog of cAMP, or FSK (5 ϫ 10 Ϫ6 M), an activator of adenylyl cyclase, significantly inhibited OPG secretion (Fig. 5A) , and dBcAMP also led to a decrease in OPG expression (Fig. 5B) . As a consequence of its well-known stimulation of cAMP production (28, 42) , CGRP significantly increased PKA activity in hOB, starting after 2 min and lasting up to 90 min, with maximum activation after 15 min (Fig. 6A) ; preincubation with the PKA inihibitor H89 (2 ϫ 10 Ϫ6 M) 30 min before the addition of 10 Ϫ8 M CGRP at each time point (2, 15, 30, 60, and 90 min) prevented CGRP-induced PKA activation (Fig. 6B) . Preincubation of hOB with H89 (30 min 1 mRNA levels were quantified using the comparative threshold cycle (CT) method in which the reactions are characterized by the point in time during cycling when the amplification of a PCR product is first detected. The amount of target mRNA in each sample directly correlates with the CT. For each sample, the amount of the target mRNA, CT(target gene), was normalized to the amount of housekeeper mRNA, CT(GAPDH), designated as a calibrator, to give ⌬CT (CTtarget gene Ϫ CTGAPDH). The amounts of target mRNA in the samples were expressed using the formula, 2
Ϫ⌬⌬CT , where ⌬⌬CT ϭ ⌬CT(treated sample) Ϫ ⌬CT(untreated sample). before CGRP) inhibited the effect of 10 Ϫ8 M CGRP on OPG secretion after 48 h of treatment (Fig. 7) .
In hOB, no detectable levels of RANKL mRNA or secreted protein were observed in the conditioned media under baseline conditions or after 10 Ϫ8 M 1,25(OH) 2 D 3 treatment. Cytofluorimetry showed that the percentage of RANKL-positive cells in the hOB culture was very low and not significant (data not shown). To examine the possible effect of the reduced OPG secretion induced by CGRP in hOB on osteoclastogenesis, PBMCs were cultured for 21 days in conditioned media obtained from hOB treated with or without CGRP 10 Ϫ8 M for 48 h, and in the presence of M-CSF (25 ng/ml) and RANKL (0.1 or 30 ng/ml). The presence of osteoclast-like cells was evaluated by counting the number of multinucleated TRAPϩ cells per well.
In the presence of the subeffective dose of RANKL (0.1 ng/ml), the conditioned media of untreated hOB did not induce the formation of TRAPϩ multinucleated cells. However, the conditioned media of CGRP-treated hOB induced the formation of few TRAPϩ multinucleated cells (Fig. 8) . In the presence of the effective dose of RANKL (30 ng/ml), the conditioned media of CGRP-treated hOB induced a significant increase (P Ͻ 0.01) in the number of TRAPϩ multinucleated cells compared with the number of TRAPϩ multinucleated cells formed in the presence of the conditioned media of the untreated hOB (Fig. 9C) . Similarly, a significant increase (P Ͻ 0.05) in cathepsin K secretion was observed in the supernatants of PBMC exposed to the conditioned media of CGRP-treated hOB in presence of the effective dose of RANKL (Fig. 9D) .
DISCUSSION
The results of this study show that hOB express CLR, RAMP1 and RAMP2, but not RAMP3. The expression of CLR and RAMP1 indicates that hOB have functional receptors for CGRP insofar as CLR and RAMP1 seem to behave as a unitary complex acting as a CGRP receptor. In fact, the coexpression of the two proteins is required to transfer the receptor to the cell surface and for the endocytosis of the ligand-receptor complex after CGRP binding and receptor activation (15) . The coexpression of CLR and RAMP2 gives rise to a receptor with greater affinity for adrenomedullin (23, 29) , a member of the calcitonin peptide family, which, like CGRP, has mitogenic effects on osteoblasts (9) . At variance with published findings of the expression of all three RAMPs in primary cultures of fetal rat osteoblasts (35) , the lack of RAMP3 expression in hOB indicates that the expression of this family of proteins is species specific.
Our results also show that CGRP inhibits OPG production in hOB in a dose-dependent manner, and that this occurs at both mRNA and protein levels. Pretreatment with the CGRP receptor antagonist CGRP 8 -37 abolished this inhibition of OPG expression and production, thus indicating that the effects are specific and receptor mediated. The inhibitory action of CGRP requires the activation of the cAMP/PKA pathway, as suggested by the finding that impaired PKA activity prevented the action of CGRP, and the fact that the action of CGRP is mimicked by dBcAMP and forskolin further indicates that the ability of CGRP to inhibit OPG expression and production depends on the induction of cAMP and subsequent downstream events mediated by PKA.
Analysis of the human OPG promoter has revealed putative consensus cAMP response element-binding sites at positions Ϫ289 and Ϫ104 (4). Because cAMP response element-binding activity is regulated by protein kinases (such as PKA, calmodulin-dependent protein kinase, and MAPK), it is possible that, by activating the cAMP/PKA cascade, CGRP inhibits OPG gene expression by means of a direct genomic mechanism.
The suppression of OPG secretion was ϳ45%, and so it is possible that other intracellular pathways in addition to cAMP may be involved. Bergh et al. (4) have described a model in which the calcium signals generated by the regulatory activity of L-type voltage-sensitive channels can regulate OPG expression and secretion by means of calmodulin-sensitive protein kinase signaling; blocking the activity of these channels reduces the level of OPG expression and secretion in primary calvarial organ (4) .
This study shows that the reduction of OPG secretion and expression induced by CGRP favors the development of multinucleated TRAPϩ cells from PBMC, as expected from the actual understanding of the molecular triad OPG/RANK/ RANKL (42) . It follows that CGRP, by modulating at least one element of the triad, enhances the differentiation of committed precursors into mature cells to induce bone resorption. This pro-osteoclastogenic effect of CGRP may be the prerequisite to exert the generally acknowledged bone anabolic action of the peptide. It is indeed well established that the hierarchical nature of bone remodeling to increase bone mass implies osteoclast activation and formation as first mandatory events (33) . CGRP appears therefore to be a member of the family of anabolic factors that displays a complex biphasic activation of bone remodeling. Other hormones that increase cAMP accumulation, such as PTH and the prostaglandins, reduce OPG expression in osteoblasts (5, 12, 40) , and are simultaneously potent stimulators of bone formation (37) . In fact, PTH inhibits OPG expression and stimulates RANKL production through PKA activation in murine bone marrow cells (26) thus leading to enhanced osteoclastogenesis (17) . Similarly, prostaglandins activate bone resorption by stimulating RANKL expression (27) , an effect mediated by the specific prostaglandin EP1 receptor (43) .
Measurements of RANKL in hOB after exposure to CGRP may have given a better insight into the peptide's effect on the cross-talk between bone forming and bone resorbing cells but, as recently reported by others (41) , neither the expression nor the secretion of RANKL reached detectable levels thus hampering the possibility of evaluating the cross-talk signal in coculture of human osteoblasts and osteoclasts.
The finding that CGRP favors osteoclast formation via its pro-osteoclastogenic effect on the OPG/RANK/RANKL triad apparently conflicts with its direct inhibitory action on bone resorption (1, 8, 21, 49) . However, the cellular events (formation, activation, and survival of osteoclasts) involved in the bone resorption phases, are subjected to a complex of other factors, besides OPG/RANK/RANKL, that may have an impact on bone mass outcome at each remodeling cycle (42) . Therefore, it can be suggested that CGRP by activating bone remodeling, contributes to the fine adjustment of this process, favoring the gain or loss of bone mass depending on the local demand. In particular, this modulatory function may be important in bone fractures, where an increase of CGRP-containing nerve fibers (18) and circulating CGRP levels have been shown Ϫ8 M) and untreated hOB. Data are the means Ϯ SE of 3 experiments performed with cells from three different donors; **P Ͻ 0.01, *P Ͻ 0.05 vs. conditioned media of untreated cells, Student's t-test. (36) . When bone formation must offset bone resorption, as in the case of bone repair with highly activated bone remodeling, CGRP activity may help fulfil the requirements of regeneration processes. The anabolic role of CGRP in bone is further supported by the fact that mice with the selective deletion of ␣-CGRP have osteopenia caused by a reduced rate of bone formation (38) .
In conclusion, this study suggests that CGRP acts as a modulator of the OPG/RANKL/RANK system by reducing OPG release and expression by hOB, thus favoring osteoclast formation with subsequent activation of the bone remodeling events. CGRP may play a role in modulating the fine balance between bone resorption and bone formation, thus leading to the generally acknowledged anabolic outcome.
